Agrawal Biotech Profile
Key Indicators
- Authorised Capital ₹ 2.50 M
- Paid Up Capital ₹ 2.50 M
- Company Age 2 Year, 9 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 4.65 Cr
About Agrawal Biotech
Agrawal Biotech Private Limited (ABPL) is a Private Limited Indian Non-Government Company incorporated in India on 20 April 2022 (Two years and nine months 12 days old ). Its registered office is in Indore, Madhya Pradesh, India.
The Company is engaged in the Agriculture Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 2.50 M and a paid-up capital of Rs 2.50 M.
The company currently has active open charges totaling ₹4.65 Cr.
Chetan Agarwal, Shraddha Agrawal, and Rahul Agrawal serve as directors at the Company.
Company Details
- Location
Indore, Madhya Pradesh, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media-
Corporate Identity Details
- CIN/LLPIN
U15300MP2022PTC060509
- Company No.
060509
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
20 Apr 2022
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Gwalior
Industry
Who are the key members and board of directors at Agrawal Biotech?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Chetan Agarwal  | Director | 04-Jan-2023 | Current |
| Shraddha Agrawal | Director | 04-Jan-2023 | Current |
| Rahul Agrawal | Director | 20-Apr-2022 | Current |
Financial Performance of Agrawal Biotech.
Agrawal Biotech Private Limited, for the financial year ended 2023, experienced no change in revenue, with a 0% increase. The company also saw a no change in profitability, with a 0% increase in profit. The company's net worth witnessed no change by increase of 0%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets | |||||||
| Profit or Loss | |||||||
| Net Worth | |||||||
| EBITDA |
What is the Ownership and Shareholding Structure of Agrawal Biotech?
Unlock access to Agrawal Biotech's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Charges (Loans)
₹46.50 M
₹0
Charges Breakdown by Lending Institutions
- Axis Bank Limited : 4.65 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 11 Jan 2024 | Axis Bank Limited | ₹4.65 Cr | Open |
How Many Employees Work at Agrawal Biotech?
Agrawal Biotech has a workforce of 0 employees as of Mar 28, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Agrawal Biotech, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Agrawal Biotech's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
